...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Great Presetation today

....Yes someone could invest in a 100% owned subsidiary, the only thing that changes is the subsidiary is no longer 100% owned.  That being said dilution then only occurs at the subsidiary level....

That makes sense.  Eastern has been buying shares of ZenEp, not ZCC. So I assume if ZenEp were sold, Eastern would get more than 1/3 of the proceeds off the top.  The rest would go to ZCC to be (possibly, hopefully) distributed amongst the commoners.

Zenith Epigenetics Closes US$24.6 Million Private Placement
May 16, 2016

CALGARY, May 16, 2016 /CNW/ - Zenith Epigenetics Corp. ("Zenith" or the "Company") today....Eastern holds 47,760,500 common shares of Zenith, representing approximately 38.6 percent of Zenith's issued and outstanding common shares....

Share
New Message
Please login to post a reply